Salidroside (**1**), a glucoside of tyrosol (**3**)[@b1][@b2], was well established as the main bioactive component of *Rhodiola*[@b3][@b4] (also known as "Tibetan Ginseng"), which is a highly valued medicinal herb that grows at high altitude and in cold regions, such as the slopes of the Himalayas. Its benefits date back to a long history of folk use. It is known to play an important role in adaptogenic effects, like treating anoxia, microwave radiation, fatigue, and slowing the aging process[@b5][@b6]. Reports have shown that it can also prevent cardiovascular diseases and cancer[@b7][@b8]. No side effects or drug interactions have been reported for *Rhodiola*[@b9]. The aglycon tyrosol (**3**) is also present in *Rhodiola* and displays multiple pharmacological effects. As a natural phenolic antioxidant, tyrosol (**3**) can protect cells against injury due to oxidation. In addition, it has been shown to play a role in the prevention of cardiovascular diseases[@b10][@b11], osteopenia[@b12], melanin pigmentation[@b13], as well as in anti-inflammatory responses[@b14].

Because of its slow growth and over-gathering, the resources of wild *Rhodiola* are on the edge of exhaustion[@b2]. Furthermore, the content of salidroside (**1**) in *Rhodiola* is relatively low[@b1]. Hence, to meet the increasing demands, considerable efforts have been made on enhancing the production of salidroside (**1**) since many years; and these include extensive field cultivation, tissue culture, and genetic engineering of *Rhodiola*[@b2][@b15][@b16][@b17]. However, these processes are expensive, time-consuming, and produce low yields, and as a result, cannot be used extensively. It is, therefore, urgent to establish alternative ways to produce salidroside (**1**).

Researchers have engineered genetically tractable microorganisms to carry out secondary metabolic pathways in plants, in order to produce a range of natural products[@b18][@b19][@b20][@b21]. Development of an effective protocol and strain for the microbial production of salidroside (**1**) using renewable feedstock might be a commercially valuable process. *Escherichia coli* (*E. coli*) has emerged as a "user-friendly" heterologous host due to its rapid growth rate, simple culture conditions, plethora of readily accessible genetic tools, and comprehensive synthetic biological framework[@b22][@b23][@b24][@b25].

While the biosynthetic pathway of salidroside (**1**) is still elusive[@b15], two pathways for the formation of tyrosol (**3**) are established in nature. The first pathway involves the conversion of [L]{.smallcaps}-tyrosine into tyramine by tyrosine decarboxylase (TDC); and further transformation of tyramine into tyrosol by tyramine oxidase (TYO) and alcohol dehydrogenase (ADH), consecutively[@b26]. Besides, tyrosol (**3**) can also be derived from yeast Ehrlich pathway, by conversion of [L]{.smallcaps}-tyrosine through the sequential action of aminotransferase, pyruvate decarboxylase, and ADHs ([Fig. 1a](#f1){ref-type="fig"})[@b27][@b28]. In a study by Yu *et al*., the glucosyltransferase UGT73B6 was isolated from *Rhodiola sachalinensis*, and the enzyme was found to be able to convert tyrosol into salidroside[@b29].

In the present study, we first engineered *E. coli* to synthesize tyrosol (**3**) from glucose by the integration of a yeast pyruvate decarboxylase ARO10 into the [L]{.smallcaps}-tyrosine pathway ([Fig. 1](#f1){ref-type="fig"}). Subsequently, we improved production of tyrosol (**3**) through enhancement of metabolic flux towards 4-hydroxyphenylpyruvate (**2**) by the metabolic engineering of [L]{.smallcaps}-tyrosine pathways into *E. coli* ([Fig. 1b](#f1){ref-type="fig"}). Finally, we introduced plant-derived UGT73B6 into this recombinant *E. coli* strain and accomplished the unprecedented biosynthesis of salidroside (**1**) in a microbial system. Moreover, the *Rhodiola*-derived glycosyltransferase UGT73B6 catalyzed the formation of icariside D2 (**4**) by adding glucose to the phenolic position of tyrosol (**3**), which was reported for the first time regarding the function of the glucosyltransferase.

Results
=======

Construction of the tyrosol biosynthetic pathway in *E. coli*
-------------------------------------------------------------

First, we attempted to construct a metabolic pathway for the production of tyrosol (**3**) in *E. coli*. In the yeast Ehrlich pathway, the key intermediate, 4-hydroxyphenylpyruvate (**2**), is derived from [L]{.smallcaps}-tyrosine by transamination; while in *E. coli*, this compound is a native metabolite in the [L]{.smallcaps}-tyrosine biosynthetic pathway. Compound **2** was decarboxylated to 4-hydroxyphenylacetaldehyde (**5**) by the expression of a pyruvate decarboxylase gene *ARO10* from *Saccharomyces cerevisiae*[@b27]. Compound **5** was reduced to tyrosol by the endogenous ADHs in *E. coli* ([Fig. 1a](#f1){ref-type="fig"}). Besides reduction to tyrosol, the intermediate compound **5** could also be oxidized to 4-hydroxyphenylacetate (**6**) by the endogenous phenylacetaldehyde dehydrogenase (FeaB or PadA) of *E. coli*[@b26]. To enhance the production of tyrosol, we constructed a *feaB*-knockout strain (BMGF0, [Table 1](#t1){ref-type="table"}), thus shutting off the synthesis pathway of compound **6**.

As shown in [Fig. 2](#f2){ref-type="fig"}, the *feaB*-knockout strain harboring the *ARO10* gene (BMGF1) was able to produce a new compound corresponding to peak I ([Fig. 3a](#f3){ref-type="fig"}) in the HPLC chromatogram with identical retention time as tyrosol (**3**). The structure was further confirmed by a positive high-resolution electrospray mass spectrometry (HR-ESI-MS) at m/z 121.0680 \[M-H~2~O + H\]^+^ ([Fig. 3b](#f3){ref-type="fig"}). The experiment demonstrated that tyrosol (**3**) production from glucose was enabled in *E. coli* by the introduction of phenylpyruvate decarboxylase ARO10 from yeast. Fermentation led to the production of 128.3 mg/L of tyrosol (**3**) from 2% glucose in flask cultures.

Enhancement of tyrosol production by elimination of competitive pathways and negative regulation
------------------------------------------------------------------------------------------------

To improve the capacity of the strain for tyrosol (**3**) production from glucose, we further enhanced metabolic flux towards 4-hydroxyphenylpyruvate (**2**) in *E. coli*. The negative regulatory and competing pathways were eliminated in the biosynthesis of [L]{.smallcaps}-tyrosine ([Fig. 1b](#f1){ref-type="fig"}). In concrete terms, the pathway-specific transcriptional regulatory gene, *tyrR*, was inactivated, which in turn led to the enhanced expression of genes relevant to [L]{.smallcaps}-tyrosine biosynthesis, including *aroG*, *tyrA*, and *aroL*, encoding 3-deoxy-[D]{.smallcaps}-arabino-heptulosonate (DAHP) synthase, chorismate mutase/prephenate dehydrogenase, and shikimate kinase, respectively[@b30][@b31]. Both *pykA* and *pykF* genes encoding the pyruvate kinase isozymes were knocked out to block the metabolic flux associated with the conversion of phosphoenolpyruvate (PEP) to pyruvate, further intensifying the availability of PEP to synthesize more DAHP. In addition, the *pheA* gene was deleted to prevent the competitive [L]{.smallcaps}-phenylalanine biosynthesis, thereby driving chorismate to the production of 4-hydroxyphenylpyruvate (**2**) and [L]{.smallcaps}-tyrosine ([Fig. 1b](#f1){ref-type="fig"}). Following these manipulations in the genome of the tyrosol-producing *E. coli* strain BMGF1, the yield of tyrosol (**3**) was found to increase gradually from 128.3 mg/L to 603.9 mg/L using 2% glucose under the 50 mL shake-flask cultivation ([Fig. 3c](#f3){ref-type="fig"}). Among the four targeted genes, the deletion of *pheA* contributed considerably to the increment of tyrosol (**3**) yield, from 347.3 mg/L to 603.9 mg/L ([Fig. 3c](#f3){ref-type="fig"}).

Enhancement of tyrosol production by overexpression of pathway genes
--------------------------------------------------------------------

In order to further enhance the metabolic flux towards 4-hydroxyphenylpyruvate (**2**), several key genes in the pathway were expressed ([Fig. 1b](#f1){ref-type="fig"} and [2](#f2){ref-type="fig"}). Firstly, the feedback-resistant mutants, *aroG*\**^syn^* (D146N) and *tyrA*\**^syn^* (M53I; A354V) were expressed under the control of a constitutive P~LtetO−1~ promoter. The *aroG* encoding DAHP synthase and *tyrA* encoding chorismate mutase/prephenate dehydrogenase, catalyzed formations of DAHP or 4-hydroxyphenylpyruvate (**2**) respectively, in the biosynthesis of [L]{.smallcaps}-tyrosine. These two committed steps were tightly regulated by aromatic amino acids. The feedback-resistant derivatives, AroG\* and TyrA\* enzymes, are usually used to overcome the inhibition of the end product to enhance the accumulation of [L]{.smallcaps}-tyrosine[@b32]. Secondly, we expressed the *ppsA* and *tktA* genes, aiming to increase the supply of the two precursors involved in the aromatic amino acid biosynthesis, PEP and erythrose-4-phosphate (E4P). This step was based on the early reports that overexpression of *ppsA* and *tktA* genes encoding phosphoenolpyruvate synthase and transketolase, respectively, increases the yield of DAHP, approaching the theoretical limit yield[@b33][@b34]. Thirdly, *aroE*, *aroD* and *aroB^op^*, encoding shikimate dehydrogenase, 3-dehydroquinate (DHQ) dehydratase, and DHQ synthase, respectively, were overexpressed to further tune up the biosynthesis of compound **2**. AroE, instead of its isozyme YdiB, was used owing to its binding specificity to shikimate, a crucial metabolite in the common pathway of aromatic amino acids; in contrast, YdiB was reported to favor formation of the by-product, quinate[@b35]. In a previous study, Juminaga et al. reported a relatively low level of AroB protein in *E. coli*, and analysis of the *aroB* nucleotide sequence revealed several rare codons at the beginning of the gene sequence[@b36]. To improve *aroB* expression, the first 15 codons were optimized by removing rare codons[@b36] designated as *aroB^op^*, thereby improving the production of AroB proteins. We assembled the genes of [L]{.smallcaps}-tyrosine from the aforementioned pathway into three operons as gene clusters: P~LtetO−1~-tyrA\*^syn^-aroG\*^syn^-ppsA (operon 1), P~lacUV5~-tktA-aroE (operon 2), and P~lacUV5~-aroD-aroB^op^ (operon 3). These genes were sequentially cloned into the vector pBb0, a derivative of pBbA5c, to yield the plasmids pBb1 with operon 1, pBb2 with operons 1 and 2, and pBb3 with all 3 operons. These plasmids were individually transferred into the *E. coli* strain BMGA, harboring the plasmid pTrc1, thus generating strains BMGA3, BMGA4, and BMGA5. The yield of tyrosol (**3**) in these strains was found to be elevated to 752.6 mg/L, 824.9 mg/L, and 926.9 mg/L, progressively ([Fig. 3d](#f3){ref-type="fig"}).

Glucosylation of tyrosol in the recombinant *E. coli* strain
------------------------------------------------------------

UGT73B6 isolated from the plant *R. sachalinensis* was reported to display the glucosylation activity, thereby converting tyrosol (**3**) to salidroside (**1**). UGT73B6 was codon-optimized to make it suitable for its expression in *E. coli*. It was then introduced into the tyrosol (**3**) overproducing strain, BMGA5, to evaluate the production of salidroside. The resulting strain was designated as BMGA6.

The supernatant of the BMGA6 fermentation broth was first analyzed by HPLC and HR-ESI-MS, and further compared with the standard salidroside (**1**). As shown in [Fig. 4a](#f4){ref-type="fig"}, the strain BMGA6 carrying *73B6^syn^* produced two new compounds besides tyrosol (**3**), which corresponded to the peaks II and III in the HPLC chromatogram. Compound II showed a retention time, *t*~R~, of 8.8 min ([Fig. 4a](#f4){ref-type="fig"}; peak II) and the molecular ion \[M + NH~4~\]^+^ at m/z = 318.2950 ([Fig. 4b](#f4){ref-type="fig"}), which synchronized with the standard salidroside (**1**). The structure was further confirmed by ^1^H NMR spectroscopic analysis ([Fig. S1](#s1){ref-type="supplementary-material"}) and compared to that of standard salidroside (**1**)[@b37]. The other compound ([Fig. 4a](#f4){ref-type="fig"}; peak III, *t*~R~ 5.4 min) showed a molecular ion at m/z 318.1534 (\[M + NH~4~\]^+^), as determined by HR-ESI-MS ([Fig. 4d](#f4){ref-type="fig"}). We suspected the compound corresponding to peak III to be a derivative of tyrosol with glucosylation at the phenolic position ([Fig. 4c](#f4){ref-type="fig"}). This compound was further purified from the extracts of the 1 L fermentation broth by semi-preparative HPLC, and analyzed by 1D and 2D-NMR spectroscopy. On the basis of ^1^H, ^13^C, COSY, HSQC, and HMBC spectroscopic analyses, the structure of compound III was unambiguously determined as icariside D2 (**4**), with the glucoside added to the hydroxyl group on the benzene ring of tyrosol (**3**), rather than on the side chain of tyrosol (**3**), as displayed by salidroside (**1**) ([Table 2](#t2){ref-type="table"}; [Fig. 4c](#f4){ref-type="fig"}). Icariside D2 (**4**) is a homolog of gastrodin (**7**) ([Fig. 4c](#f4){ref-type="fig"}), with an extra methylene bridge (-CH~2~- unit) in the side chain. The phenolic glucoside, gastrodin (**7**), is a main active constituent of the widely known Chinese medicine, *Tianma* (*Gastrodia elata*) Blume, and has been used to treat various ailments, such as headache, dizziness, vertigo, and convulsive illnesses, as part of the traditional medicine[@b38]. As a homologue of gastrodin (**7**), investigation on the potential pharmaceutical value of icariside D2 may prove beneficial. The productions of salidroside (**1**), icariside D2 (**4**) and tyrosol were further measured in the fermentation broth of BMGA6, with titers of 56.9 mg/L, 63.2 mg/L and 764.6 mg/L, respectively.

Discussion
==========

To the best of our knowledge, this is the first report on the development of a unique artificial biosynthetic pathway in *E. coli* for the production of salidroside (**1**) from glucose. The protocol was successfully carried out using yeast pyruvate decarboxylase ARO10, endogenous ADHs, and glycosyltransferase UGT73B6 from *Rhodiola*. In order to streamline metabolic flux towards the production of aglycon tyrosol (**3**) from glucose, metabolic engineering of the [L]{.smallcaps}-tyrosine biosynthesis pathway (including gene deletion and overexpression) was performed. The regulatory gene, *tyrR*, and several genes involved in other competing pathways, *pykA*, *pykF*, and *pheA*, were deleted from the *E. coli* chromosome. A combined expression of *tyrA* (*tyrA*\**^syn^*), *aroG* (*aroG*\**^syn^*), *ppsA*, *tktA*, *aroE*, *aroD*, and *aroB^op^*, coding for various enzymes of the [L]{.smallcaps}-tyrosine pathway, was found to be efficient in elevating the production of tyrosol (**3**). Finally, a maximum yield of 56.9 mg/L was obtained for salidroside (**1**). The present research may lead to the development of a simple and economical process for the large-scale microbial production of salidroside (**1**). In the future, the supply of UDP-glucose needs to be enhanced via metabolic engineering for the production of high levels of salidroside. Improvement in the enzymatic activities of the glucosyltransferase, UGT73B6, by protein engineering is also currently being undertaken in our lab.

It was interesting to discover the enzymatic activity of UGT73B6 attaching glucose to the phenol position of tyrosol (**3**), which was not observed in any previous study[@b29]. Nevertheless, the functional diversity and promiscuity of plant-specific UGTs are common, and many UGTs are known to exhibit broad substrate specificity[@b39]. Glycosyltransferases are important tools to generate novel glycosylated derivatives[@b40][@b41]. We identified UGT73B6 as a glucosyltransferase through *in vivo* experiments; in the process, we have revealed a flexible UGT, which might present a novel tool to produce natural glycosylated products with improved biological activities.

Methods
=======

Bacterial strains and plasmids
------------------------------

The bacterial strains and plasmids used in this study are listed in [Table 1](#t1){ref-type="table"}. All gene-deletion strains were derived from *E. coli* MG1655 by using the classical λ Red homologous recombination method[@b42]. The primers used for the amplification of DNA fragments for targeted genes are listed in [Table S1](#s1){ref-type="supplementary-material"}.

Pathway and plasmid construction
--------------------------------

The artificially constructed pathway of salidroside (**1**) production in *E. coli* is shown in [Fig. 1](#f1){ref-type="fig"}. All the PCR primers are listed in [Table S2](#s1){ref-type="supplementary-material"}. The constructed plasmids were confirmed by enzyme digestion and DNA sequencing. A list of plasmids and strains used in this study are presented in [Table 1](#t1){ref-type="table"}.

The codon-optimized variant of the *UGT73B6* gene (GenBank, AY547304) and two mutant genes encoding AroG\* (\*feed-back inhibition resistance) (Asp146 to Asn)[@b43] and TyrA\* (Met53 to Ile and Ala354 to Val)[@b44], were synthesized by Shanghai Generay Biotech Co. Ltd., and denoted as *73B6^syn^*, *aroG\*^syn^*, and *tyrA*\**^syn^*, respectively. The corresponding amino acids for the synthesized genes are provided in [Supplementary Table S3](#s1){ref-type="supplementary-material"}. The pyruvate decarboxylase gene, *ARO10* (GenBank, NC_001136), was amplified from *Saccharomyces cerevisiae* S288 genome, while the genes *ppsA*, *aroE*, *aroD*, and *aroB* were amplified from the genome of *E. coli* MG1655. To improve the expression of *AroB*, rare codons found within the first 15 codons of *AroB* were optimized[@b35] and designated as *aroB^op^*. All the genes were designed and amplified with their own ribosome binding sites.

Two plasmid systems were used to construct the biosynthetic pathways of tyrosol (**3**) and salidroside (**1**). pTrcHisB was used as a vector for constructing pTrc series plasmids, which contained the genes, *ARO10* and *UGT73B6* ([Fig. 2](#f2){ref-type="fig"}). *ARO10* was cloned into pTrcHisB, generating the plasmid pTrc1. The *73B6*^syn^ gene was initially cloned into pTrcHisB, and PCR was carried out with the resulting plasmid to amplify the gene fragment, *73B6*^syn^, under the control of a trc promoter. Subsequently, the PCR product was digested and cloned into pTrc1 to generate plasmid pTrc2, carrying *ARO10* and *73B6*^syn^.

pBbA5c[@b45] was used as the starting plasmid to construct the gene clusters of [L]{.smallcaps}-tyrosine pathway and was further modified with new multi-cloning sites, thereby yielding pBb0. *tyrA*\**^syn^*, *aroG*\**^syn^*, and *ppsA* were amplified via PCR and sequentially cloned into pBb0, in an operon driven by the P~Ltet~ promoter, thus generating plasmid pBb1. The genes *tktA*, and *aroE* were sequentially cloned into pBb0, and PCR was conducted with the resulting plasmid harboring *tktA* and *aroE* as the template, to amplify the fragment containing the gene cluster. The DNA fragment was cloned into pBb1 as a second operon under the control of a P~lacUV5~ promoter, yielding plasmid pBb2. Similarly, *aroD* and *aroB^op^* genes were incorporated into pBb2 driven by a P~lacUV5~ promoter, generating plasmid pBb3 ([Table 1](#t1){ref-type="table"}; [Fig. 2](#f2){ref-type="fig"}). The detailed protocols for cloning and plasmid construction are described in the [Supplementary Material](#s1){ref-type="supplementary-material"}.

Culturing of the recombinant *E. coli* strains
----------------------------------------------

All strains were cultivated in modified M9 medium (M9Y) containing 1 × M9 minimal salts, 5 mM MgSO~4~, 0.1 mM CaCl~2~, 2% (w/v) glucose, supplemented with 0.025% (w/v) yeast extract. Appropriate amounts of antibiotics (25 μg/mL chloramphenicol, 50 μg/mL ampicillin, and 100 μg/mL streptomycin) were supplemented to the medium, when needed. Isopropyl β-[D]{.smallcaps}-thiogalactopyranoside (IPTG) was added into the medium at a final concentration of 0.1 mM.

Single colonies of the engineered *E. coli* strains harboring the recombinant plasmids were inoculated in 5 mL liquid LB medium containing appropriate antibiotics, and allowed to grow overnight at 37°C. The culture was then diluted 1:100 with 50 mL fresh LB medium and incubated in a gyratory shaker incubator at 37°C, 200 rpm. When the absorbance of the culture (measured at 600 nm) reached to about 0.6--0.8, IPTG was added at 25°C for 24 h to induce recombinant protein expression. Subsequently, the cells were recovered by centrifugation, washed once, resuspended in 50 mL M9Y medium, and cultured at 30°C for 48 h for the extraction of compounds and further analysis. The shake-flask experiments were conducted in triplicates.

Analysis of secondary metabolites from the recombinant *E. coli* strains
------------------------------------------------------------------------

For the analysis of tyrosol (**3**), 10 μL supernatant from the fermented broth was analyzed by High-performance liquid chromatography (HPLC) while for the analysis of salidroside (**1**) and icariside D2 (**4**), 50 μL of the supernatant was evaluated through HPLC. Standard tyrosol and salidroside (Aladdin chemistry Co. Ltd) were used as reference for the analysis. HPLC analysis was performed on an SHIMADZU system with UV detector. The products were detected at 225 nm under room temperature. The conditions used were as follows: solvent A = 0.1% methanoic acid in H~2~O; solvent B = methanol; flow rate = 1 mL min^−1^; 0--20 min 80% A and 20% B; 21--45 min 80% A and 20% B to 100% B (linear gradient); 46--50 min 100% B. The column used was Agela Innoval C18, 4.6 × 250 mm with a particle size of 5 μm. For the quantification of tyrosol (**3**), salidroside (**1**), and icariside D2 (**4**) in culture media, standard calibration curves were generated with a series of known concentrations of the standard dissolved in culture media. The R^2^ coefficient for the calibration curves was higher than 0.999. Samples were diluted as required, in order to fall into the concentration range of the calibration curves.

HPLC-MS analysis
----------------

HPLC-MS was performed on an Agilent 1260 system with 1260 Infinity UV detector and a Bruker microQ-TOF II mass spectrometer equipped with an ESI ionization probe. For the analysis of tyrosol and its derivatives, the HPLC conditions used were as follows: solvent A = 0.144% ammonium acetate in H~2~O; solvent B = methanol; flow rate = 1 mL min^−1^; 0--5 min 95% A and 5% B, 6--45 min 95% A and 5% B to 100% B (linear gradient), and 46--55 min 100% B. The column used was Agela Innoval C18, 4.6 × 250 mm with a particle size of 5 μm. The products were detected at 225 nm.

Isolation of salidroside (1) and icariside D2 (4)
-------------------------------------------------

To extract salidroside (**1**) and icariside D2 (**4**) from the broth, 1 L of the fermentation broth was centrifuged after cultivation, and the supernatant was incubated with resin (HP-20) for 2 h. The resin was subsequently collected by centrifugation, washed once with distilled water and then washed with 50 mL methanol. Further, the methanol layer was collected by centrifugation and concentrated under reduced pressure. The residue was then dissolved in 2 mL methanol, and was purified by semi-preparative HPLC performed on a Shimadzu LC-6 AD with SPD-20A detector (solvent A = 0.1% methanoic acid in H~2~O; solvent B = methanol; solvent A/B = 3:1; flow rate = 8 mL min^−1^). A Shim-pack PREP-ODS (H) kit (20 × 250 mm; particle size, 5 μm) was used.

NMR analysis
------------

NMR spectra were recorded on a Bruker AVANCE III 600 spectrometer using TMS as the internal standard, and chemical shifts were recorded as δ values. Details of the NMR data are presented in [Table 2](#t2){ref-type="table"}.
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![Metabolic pathways for tyrosol (3), salidroside (1), and icariside D2 (4) biosynthesis in recombinant *E. coli* strains from glucose.\
(a) The artificial synthetic pathway for salidroside (**1**) production from **2** consisting of enzymes, yeast pyruvate decarboxylase ARO10, endogenous ADH of *E. coli*, and UGT73B6 from *Rhodiola*. (b) Metabolic flux enhancement of precursor supply of **2**. Single arrows represent one-step conversions, while single dashed arrows represent multiple steps. Bold arrows represent gene overexpression. The dashed lines indicate feedback inhibitions. The fork arrows represent gene deletion. Abbreviations: G6P, 6-phosphate-D-glucose; PYR, pyruvate; G3P, glyceraldehyde-3-phosphate; F6P, fructose-6-phosphate; PEP, phosphoenolpyruvate; E4P, erythrose 4-phosphate; UDP-glucose, Uridine 5′-diphosphoglucose; DAHP, 3-deoxy-arabino-heptulonate7-phosphate; DHQ, 3-dehydroquinic acid; CHA, chorismic acid; DHS, dehydroshikimate; SHIK, shikimate; S3P, shikimate 3-phosphate; EPSP, 5-enolpyruvylshikimate-3-phosphate; CHA, chorismate; PP, phenylpyruvate; PHE, phenylalanine; 4HPP, 4-hydroxyphenylpyruvate; TYR, tyrosine; AroG\*, feedback resistant mutant of AroG; TyrA\*, feedback resistant mutant of TyrA; FeaB, phenylacetaldehyde dehydrogenase; ADH, alcohol dehydrogenase.](srep06640-f1){#f1}

![Plasmids construction.\
Plasmids pBb1, pBb2 and pBb3 containing [L]{.smallcaps}-tyrosine pathway genes were used to stepwise enhance metabolic flux toward 4-hydroxyphenylpyruvate (**2**); plasmids pTrc1 and pTrc2 harbored genes encoding for enzymes involved in biosynthesis of tyrosol and salidroside.](srep06640-f2){#f2}

![Production of tyrosol (3) in recombinant strains.\
(a) HPLC analysis of tyrosol (**3**) production in the fermentation supernatant of recombinant strains. 1. BMGF1, *E. coli* MG1655 (Δ*feaB*) harboring plasmid pTrc1 (P~Trc~-ARO10); 2. BMGF0, *E. coli* MG1655 (Δ*feaB*) harboring empty vector pTrcHisB (control); 3. Standard tyrosol (**3**). (b) Mass spectrum of tyrosol (**3**) from fermentation supernatant of strain BMGF1. (c) The influence of gene deletions on the tyrosol production. All the strains derived from BMGF1. The genes *pykA*, *tyrR, pykF* and *pheA* were sequentially deleted to enhance the metabolic flux toward 4-hydroxyphenylpyruvate (**2**), resulting strains BMGP1, BMGT1, BMGK1 and BMGA1. (d) The influence of genes overexpression on the tyrosol production. BMGA2, BMGA3, BMGA4 and BMGA5 were derived from BMGA1 harboring empty vector pBb0 (as control), pBb1 (P~LtetO−1~-tyrA\*^syn^-aroG\*^syn^-ppsA), pBb2 (P~LtetO−1~-tyrA\*^syn^-aroG\*^syn^-ppsA and P~lacUV5~-tktA-aroE) and pBb3 (P~LtetO−1~-tyrA\*^syn^-aroG\*^syn^-ppsA, P~lacUV5~-tktA-aroE and P~lacUV5~-aroD-aroB^op^), respectively. Three replicates were performed, and the error bars represented standard deviation.](srep06640-f3){#f3}

![Salidroside (1) and icariside D2 (4) were produced by metabolically engineered strain carrying *Rhodiola*-derived glycosyltransferase.\
(a) HPLC analysis of tyrosol (**3**) and glycosylated derivatives in fermented supernatant sample of strains. 1. BMGA6 derived from BMGA5 by introduction of glycosyltransferase UGT73B6; 2. BMGA5 was a tyrosol over-producing strain; 3. Tyrosol (**3**) and salidroside (**1**) standard. (b) HR-ESI-MS of salidroside (**3**) from fermented supernatant of BMGA6. (c) Gastrodin (**7**), a main bioactive component from *Tianma* and its homolog icariside D2 (**4**). (d) HR-ESI-MS of icariside D2 (**4**) from fermented supernatant of strain BMGA6.](srep06640-f4){#f4}

###### Bacterial strains and plasmids

  Name                                                        Description                                                        Reference
  -------------- ----------------------------------------------------------------------------------------------------- -----------------------------
  **Strains**                                                                                                                         
  BMGF                                                 *E. coli* MG1655 Δ*feaB*                                                 This study
  BMGF0                                         *E. coli* MG1655 Δ*feaB* with pTrcHisB                                          This study
  BMGF1                                           *E. coli* MG1655 Δ*feaB* with pTrc1                                           This study
  BMGP                                                       BMGF Δ*pykA*                                                       This study
  BMGP1                                                     BMGP with pTrc1                                                     This study
  BMGT                                                       BMGP Δ*tyrR*                                                       This study
  BMGT1                                                     BMGT with pTrc1                                                     This study
  BMGK                                                       BMGT Δ*pykF*                                                       This study
  BMGK1                                                     BMGK with pTrc1                                                     This study
  BMGA                                                       BMGK Δ*pheA*                                                       This study
  BMGA1                                                     BMGA with pTrc1                                                     This study
  BMGA2                                                 BMGA with pTrc1 & pBb0                                                  This study
  BMGA3                                                 BMGA with pTrc1 & pBb1                                                  This study
  BMGA4                                                 BMGA with pTrc1 & pBb2                                                  This study
  BMGA5                                                 BMGA with pTrc1 & pBb3                                                  This study
  BMGA6                                                 BMGA with pTrc2 & pBb3                                                  This study
  **Plasmids**                                                                                                                        
  pKD46                                        Red recombinase expression vector; Amp^R^                                (Datsenko and Wanner, 2000)
  pKD4                                        FRT (FLP recognition target) sites; Kan^R^                                (Datsenko and Wanner, 2000)
  pCP20                                              FLP expression vector; Amp^R^                                      (Datsenko and Wanner, 2000)
  pTrcHisB                                     pTrcHisB, pBR322 ori with P~Trc~; Amp^R^                                         Invitrogen
  pTrc1                                           pTrcHisB with P~Trc~-ARO10; Amp^R^                                            This study
  pTrc2                                    pTrcHisB with P~Trc~-ARO10-P~Trc~-UGT73B6; Amp^R^                                    This study
  pACYCDuet-1                                         P15A ori with P~T7~; Cm^R^                                                  Novagen
  pBba5c                                                    p15A ori, Cm^R^                                                 (Lee, et al., 2011)
  pBb0                                          pBbA5c with a new MCS, p15A ori, Cm^R^                                          This study
  pBb1                                    pBbA5c-MCS with P~Ltet~- tyrA\*-aroG\*-ppsA, Cm^R^                                    This study
  pBb2                        pBbA5c-MCS with P~Ltet~- tyrA\*-aroG\*-ppsA and P~lacUV5~-tktA-aroE, Cm^R^                        This study
  pBb3            pBbA5c-MCS with P~Ltet~- tyrA\*-aroG\*-ppsA, P~lacUV5~-tktA-aroE and P~lacUV5~-aroD-aroB^op^, Cm^R^           This study

###### ^1^H and ^13^C NMR, HMBC, ^1^H-^1^H COSY data for compound icariside D2 (4) (DMSO-*d*6, 600, 150 MHz, TMS, *δ* ppm)

  position      *δ*~C~      *δ*~H~ (*J* in Hz)   ^1^H-^1^H COSY      HMBC
  ---------- ------------- -------------------- ---------------- ------------
  1            101.1, CH       4.78 d (6.0)            2             3, 7
  2            73.7, CH           3.23 m                             1, 3
  3            77.1, CH           3.25 m               4              2
  4            70.2, CH           3.15 m                              3
  5            77.5, CH           3.30 m               4           1, 4, 6
  6           61.2, CH~2~     3.45 m, 3.68 m           5              4
  7            156.2, C                                                
  8            116.5, CH      6.92 d (12.0)            9            7, 10
  9            130.1, CH      7.11 d (12.0)                         7, 13
  10           133.2, C                                                
  11           130.1, CH      7.11 d (12.0)            12           7, 10
  12           116.5, CH      6.92 d (12.0)                            
  13          56.2, CH~2~      2.65 t (6.0)            14         10, 11, 14
  14          62.9, CH~2~         3.55 m                              10
  2-OH                         5.25 d (6.0)            5             2, 3
  3-OH                         5.05 d (6.0)            3               
  4-OH                         4.99 d (6.0)            4               
  6-OH                         4.53 t (6.0)            6             5, 6
  14-OH                        4.59 t (6.0)            14              

[^1]: These authors contributed equally to this work.
